Jazz Pharmaceuticals PLC (JAZZ) Business Profile

What it does

Jazz Pharmaceuticals is a biopharmaceutical company focused on medicines for rare diseases, including sleep disorders, epilepsy and cancer. Founded in 2003 and headquartered in Ireland, it is led by President and Chief Executive Officer Renee D. Gala.

Its sleep medicines include Xywav, prescribed for certain symptoms of narcolepsy and for adults with idiopathic hypersomnia, a disorder involving excessive daytime sleepiness. Xyrem is another medicine for narcolepsy. Both are shipped directly to patients or caregivers by a certified specialty pharmacy rather than stocked in retail pharmacies.

Jazz also sells Epidiolex, called Epidyolex in certain markets outside the United States. It is a cannabidiol medicine for seizures associated with rare conditions, including Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. Its oncology portfolio includes Zepzelca for small cell lung cancer, Rylaze for patients receiving certain leukemia and lymphoma treatments, and Modeyso for a type of brain tumor with a specific mutation.

Ziihera treats certain patients with HER2-positive biliary tract cancer. Jazz also received approval and launched it in first-line treatment for certain patients with HER2-positive gastroesophageal adenocarcinoma in 2026. First-line treatment is given before other systemic treatment for the condition; HER2-positive means the cancer has a particular protein targeted by the medicine.

Alongside selling approved products, Jazz develops new drug candidates and studies existing medicines for additional uses. It also acquires or licenses medicines and candidates developed by other companies.

How it makes money

Jazz earns revenue by selling prescription medicines through specialty pharmacies, distributors, hospitals and other channels. Its portfolio spans rare sleep disorders, rare epilepsy and oncology. The company also receives royalties and supply payments associated with an authorized generic version of its high-sodium oxybate medicine sold by Hikma.

Xywav is a major revenue source. Its net product sales in 2025 were $1,657.0 million, or 41% of total net product sales. Epidiolex and Epidyolex generated $1,059.2 million in net product sales in 2025, or 26% of the total. Oncology medicines Rylaze and Zepzelca generated $402.9 million and $307.3 million, respectively, in net product sales in 2025.

In the third quarter of 2026, total revenue was $1.24 billion. The company reported 35% year-over-year growth in oncology revenue and 12% growth in Xywav revenue for the quarter.

Sales depend on prescriptions, patient use and reimbursement. Narcolepsy requires long-term management, and at the end of 2025 approximately 16,175 patients were taking Xywav. Specialty pharmacy enrollment and shipping are required for Xywav and Xyrem under a safety program intended to address abuse, misuse and diversion.

Net prices are affected by discounts, rebates and other terms negotiated with pharmacy benefit managers and payors. Generic competition can also reduce the net prices of branded products. Some products generate obligations to partners: Jazz’s rights to Zepzelca and Ziihera come from licensing agreements, and higher sales of Zepzelca and Modeyso contributed to lower adjusted gross margin in the third quarter of 2026 because of royalties.

Customers and how it sells

Jazz sells medicines to intermediaries as well as to hospitals. In the United States, ESSDS is the certified specialty pharmacy that buys Xywav and Xyrem and ships them directly to patients or caregivers. Epidiolex is sold to specialty pharmacies and specialty distributors, while Modeyso is sold through the certified specialty pharmacy Onco360.

For several oncology products, Jazz sells through specialty-distributor subsidiaries of McKesson, Cencora and Cardinal. Defitelio reaches hospital customers through McKesson specialty distributors. Purchases are made on a purchase-order basis. ESSDS accounted for 42.0% of Jazz’s revenue in FY2025, and McKesson accounted for 10.0%.

Jazz markets products in the United States and internationally. Epidyolex has been launched and reimbursed in more than 40 countries. In Europe, Jazz uses wholesalers and distributors for Epidyolex and distributes certain hospital products through logistics providers, local wholesalers and distributors. Availability and approved uses vary by market.

Insurance coverage is relevant to whether patients can obtain treatment. Jazz has agreements for Xywav with all three major U.S. pharmacy benefit managers and has achieved benefit coverage for its narcolepsy and idiopathic hypersomnia indications for approximately 90% of commercial lives. Physicians and patients must enroll before Xywav or Xyrem prescriptions can be fulfilled.

Suppliers and costs

Jazz manufactures some medicines itself and uses outside manufacturers for others. Patheon and Jazz’s Athlone facility manufacture Xywav and Xyrem; Patheon makes most of the U.S. commercial supply. Siegfried has been Jazz’s only supplier of sodium oxybate, the active ingredient in Xyrem, although Jazz has the right to buy part of its worldwide requirements from other suppliers.

Jazz manufactures Epidiolex and Epidyolex at its Kent Science Park facility in the United Kingdom, where it also cultivates the cannabinoid plants used in the medicine. WuXi manufactures Ziihera in China. Jazz has an agreement with Lonza for U.S. commercial supply of Ziihera beginning in 2029.

Manufacturing and distribution of Xywav and Xyrem are restricted because the products and their active ingredients are controlled substances in the United States. Manufacturing or procuring their active ingredients in the United States requires Drug Enforcement Administration quotas.

Jazz also spends on research, clinical trials, sales and administration. In the third quarter of 2026, adjusted research and development expenses grew 11%, primarily because of evidence-generation studies and early-stage programs. Royalties on higher Modeyso and Zepzelca sales and manufacturing technology transfers contributed to a decline in adjusted gross margin.

Competitive position

Xywav and Xyrem compete in narcolepsy with Alkermes’ Lumryz, a once-nightly high-sodium oxybate. Jazz’s oxybate products also face authorized-generic competition from Hikma. Amneal and Ascent have received approval for generic high-sodium oxybate products. Jazz says high-sodium generics had little impact on the high-sodium portion of its business through the third quarter of 2026.

Epidiolex competes with other seizure treatments, including a medicine from UCB. In lung cancer, Zepzelca competes with Amgen’s tarlatamab and other treatments. Ziihera faces generic chemotherapy and other HER2-directed therapies. Jazz also competes with pharmaceutical companies to acquire or license additional products and candidates.

Xywav contains 92% less sodium than Xyrem. The FDA recognized orphan drug exclusivity for Xywav in narcolepsy through January 21, 2028 and in idiopathic hypersomnia through August 12, 2028. Jazz has coverage agreements with major pharmacy benefit managers, and its Xywav and Xyrem safety program requires a certified pharmacy and enrollment.

Our reading: Xywav’s lower sodium content, coverage and established distribution provide meaningful defenses, but competing treatments and generic applications limit their protection. Our reading: Regulatory exclusivity and patent settlements support Epidiolex’s position, although alternative seizure treatments and the possibility of earlier generic entry leave that protection conditional.

Growth opportunities

Jazz’s strategy includes expanding use of marketed medicines, developing new candidates, entering additional markets and acquiring or licensing products. Its research portfolio includes trials of existing medicines in additional diseases as well as earlier-stage programs.

Ziihera gained a new U.S. use in 2026 for first-line treatment of certain patients with HER2-positive gastroesophageal adenocarcinoma. Jazz is also evaluating zanidatamab, Ziihera’s active drug, in other HER2-expressing cancers, including breast cancer. The company estimates that 3,000 to 4,000 patients annually in the United States are eligible for Ziihera in its first-line gastroesophageal adenocarcinoma indication.

Jazz acquired Actio Biosciences in the third quarter of 2026, adding ABS 1230 to its rare epilepsy pipeline. ABS 1230 is being studied in a trial structured to support a potential future drug application. Jazz also initiated a first-in-human study of JZP269, an orexin-2 receptor agonist in its early-stage pipeline.

For Epidiolex, the FDA accepted an application for an oral capsule formulation with an April 16, 2027 decision date. Jazz is also conducting a Phase 3 study intended to support a broader epilepsy label. For Modeyso, Jazz expects a readout from the ACTION confirmatory study in the first half of 2027.

Jazz raised its 2026 total revenue guidance to $4.775 to $4.85 billion. The company also expects rare sleep revenue of $2.125 to $2.175 billion for 2026.

Structural risks

• Oxybate competition and reimbursement: Jazz expects its business to continue to depend meaningfully on oxybate revenue. Branded and generic competitors can affect sales, prices and payor coverage, while the company cannot guarantee that it will maintain adequate coverage or acceptable reimbursement terms.
• Product concentration: Xywav represented 41% and Epidiolex/Epidyolex represented 26% of total net product sales in 2025. Jazz’s results depend on maintaining or increasing sales of these products, including physician and patient acceptance and reimbursement.
• Clinical and regulatory outcomes: Trials may be delayed or halted by enrollment difficulties, safety issues, manufacturing delays or other problems. Continued approval of Ziihera for biliary tract cancer and Modeyso for its approved brain tumor indication may depend on confirmation of clinical benefit.
• Intellectual property: Patents may be challenged or found invalid or unenforceable. Epidiolex settlements allow generic entry in the very late 2030s, or earlier in specified circumstances.
• Supply and operations: Jazz relies on third parties for manufacturing and distribution. Siegfried has been its only sodium oxybate supplier, and ESSDS is the central U.S. pharmacy for Xywav and Xyrem. Trade restrictions or tariffs could also affect costs and margins.
• Debt and acquisitions: Jazz had a long-term debt principal balance of $5.4 billion as of December 31, 2025. Acquisitions can require additional capital and expose the company to integration difficulties or unanticipated liabilities.

Bottom line

Our reading

Jazz is a rare-disease drug business supported by established sleep and epilepsy products, with oncology and acquired candidates providing routes to broaden its revenue base. Its reliance on Xywav and Epidiolex makes reimbursement, competition and product protection consequential, while clinical trials and newer launches determine how far the portfolio can diversify. Manufacturing partners and debt add operational and financial exposure.